AI Article Synopsis
- Vascular calcification (VC) is a pathological condition in patients with chronic kidney disease (CKD) that can lead to serious health complications, highlighting the need for effective treatment.
- The review covers the mechanisms behind VC, assessment methods, and currently available and potential treatments, aiming to enhance understanding and management of this issue.
- Future research is expected to improve prediction and treatment strategies for VC, emphasizing the need for personalized management approaches for CKD patients.
Article Abstract
Introduction: Vascular calcification (VC) which is the pathological mineral deposition in the vascular system, predominantly at the intimal and medial layer of the vessel wall, is an important comorbidity in patients with chronic kidney disease (CKD) leading to significant morbidity and mortality while necessitating appropriate treatment. Our review aims to provide an in-depth analysis of the current understanding of VC.
Areas Covered: In this review, we first discuss the pathophysiology of VC in CKD patients, then we explain the methods to predict and assess VC. Afterwards, we provide the currently available as well as the potential therapeutic approaches of VC. We finally discuss our understanding regarding the current situation surrounding VC in our expert opinion section.
Expert Opinion: Predicting, assessing and treating VC is crucial and the future advances in the field of research surrounding VC will potentially occur in one or more of these three areas of clinical management. There is a current lack of evidence and consensus regarding specific therapeutic options for alleviating VC and this situation may not necessitate VC to be determined, detected, and documented before the available options are implemented. Regardless, the prediction and assessment of VC is still important and requires further improvement together with the developments in therapeutic alternatives. The future has the potential to bring better research which would guide and improve the management of this patient group. A more specialized approach consisting of targeted therapies and more tailored management plans for patients with CKD and VC is on the horizon.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14779072.2023.2174525 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oxidative Stress Biomarkers in Hypertension.
Curr Med Chem
January 2025
3rd Department of Cardiology, General Hospital of Thoracic Diseases 'Sotiria', National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Arterial hypertension is a silent and progressive disease with deleterious vascular implications on all target organs, including the heart, the brain, the kidneys, and the eyes. Oxidative stress, defined as the overproduction of Reactive Oxygen Species (ROS) over antioxidants, is capable of deteriorating not only the normal endothelial but also the cellular function with further cardiovascular implications. Xanthine oxidase activity, NADPH oxidase overexpression, and ROS production lead to hypertension and high arterial tone, culminating in end-organ damage.
View Article and Find Full Text PDFCorrelation analysis of estimated pulse wave velocity and severe abdominal aortic calcification: based on the National Health and Nutrition Examination Survey database.
Physiol Meas
January 2025
Department of Vascular Surgery, Jinhua Central Hospital, Jinhua City, Zhejiang Province 321000, People's Republic of China.
To investigate how severe abdominal aortic calcification (SAAC) and estimated pulse wave velocity (ePWV) relate to each other and to all-cause and cardiovascular disease (CVD) mortalities.National Health and Nutrition Examination Survey 2013-2014 data were analyzed. ePWV, computed using age and mean blood pressure, served as an independent variable.
View Article and Find Full Text PDFBase of Skull & Spinal Canal Narrowing in an Adolescent with Autosomal Recessive Hypophosphatemic Rickets Type 2.
Calcif Tissue Int
January 2025
Department of Paediatric Endocrinology, Alder Hey Children's Hospital, Liverpool, UK.
Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) is an uncommon hereditary form of rickets characterised by chronic renal phosphate loss and impaired bone mineralisation. This results from compound heterozygous or homozygous pathogenic variants in ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), a key producer of extracellular inorganic pyrophosphate (PPi) and an inhibitor of fibroblast growth factor23 (FGF23). ENPP1 deficiency impacts FGF23 and increases its activity.
View Article and Find Full Text PDFAutomated abdominal aortic calcification and major adverse cardiovascular events in people undergoing osteoporosis screening: the Manitoba Bone Mineral Density Registry.
J Bone Miner Res
January 2025
Departments of Medicine and Radiology, University of Manitoba, Winnipeg, Canada.
Vertebral fracture assessment (VFA) images from bone density machines enable the automated machine learning assessment of abdominal aortic calcification (ML-AAC), a marker of cardiovascular disease (CVD) risk. The objective of this study was to describe the risk of a major adverse cardiovascular event (MACE, from linked health records) in patients attending routine bone mineral density (BMD) testing and meeting specific criteria based on age, BMD, height loss, or glucocorticoid use have a VFA in the Manitoba Bone Mineral Density Registry. The cohort included 10 250 individuals (mean 75.
View Article and Find Full Text PDFTranscatheter mitral valve implantation in severe mitral annular calcification: a case report.
Eur Heart J Case Rep
January 2025
HerzZentrum Hirslanden, 8032 Zurich, Switzerland.
Background: Mitral annular calcification (MAC) is characterized by severe calcification of mitral annulus and might be associated with both mitral regurgitation and stenosis. It is technically challenging for both surgical and percutaneous approach and is burdened by high mortality.
Case Summary: The present case report describes a complex case of mitral steno-insufficiency (baseline transvalvular gradient = 5 mmHg, effective regurgitant orifice area 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!